tbuckley/cabot-search huggingface dataset:
Biofabrication Strategies for Oral Soft Tissue Regeneration
Authors: Maedeh Rahimnejad, Hardik Makkar, Renan Dal‐Fabbro, Jos Malda, Gopu Sriram, Marco C. Bottino
Journal: Advanced Healthcare Materials (2024)

Abstract Gingival recession, a prevalent condition affecting the gum tissues, is characterized by the exposure of tooth root surfaces due to the displacement of the gingival margin. This review explores conventional treatments, highlighting their limitations and the quest for innovative alternatives. Importantly, it emphasizes the critical considerations in gingival tissue engineering leveraging on cells, biomaterials, and signaling factors. Successful tissue‐engineered gingival constructs hinge on strategic choices such as cell sources, scaffold design, mechanical properties, and growth factor delivery. Unveiling advancements in recent biofabrication technologies like 3D bioprinting, electrospinning, and microfluidic organ‐on‐chip systems, this review elucidates their precise control over cell arrangement, biomaterials, and signaling cues. These technologies empower the recapitulation of microphysiological features, enabling the development of gingival constructs that closely emulate the anatomical, physiological, and functional characteristics of native gingival tissues. The review explores diverse engineering strategies aiming at the biofabrication of realistic tissue‐engineered gingival grafts. Further, the parallels between the skin and gingival tissues are highlighted, exploring the potential transfer of biofabrication approaches from skin tissue regeneration to gingival tissue engineering. To conclude, the exploration of innovative biofabrication technologies for gingival tissues and inspiration drawn from skin tissue engineering look forward to a transformative era in regenerative dentistry with improved clinical outcomes.
Vitamin E Acetate is Associated with Select Proinflammatory Cytokines: An Analysis of a 2020-2022 Cohort of EVALI Patients
Authors: Sean J. Callahan, Emily Beck, Denitza Blagev, Dixie Harris, Michael Lanspa, Samuel Brown, Christopher A. Reilly, Robert Paine, Kristi J. Warren
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Vitamin E Acetate is Associated with Select Proinflammatory Cytokines: An Analysis of a 2020-2022 Cohort of EVALI Patients." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Authors: Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, Davide Facchinelli, Luca Tosoni, Sara Pezone, Davide Griguolo, Giulia Ciotti, Marco Danini, Andrea Bernardelli, Rita Bresciani, Monica Cavraro, Lara Crosera, Elena De March, Michele Dell’Eva, Laura Dorotea, Luca Frison, Lara Furlani, Ilaria Gianesello, Ester Lovato, Elena Marchetti, Gianluca Morelli, Rikard Mullai, Umberto Pizzano, Simone Zoletto, Renato Fanin, Mauro Krampera, Livio Trentin, Elisabetta Calistri, Giuseppe Carli, Gianni Binotto, Mario Tiribelli
Journal: Blood Cancer Journal (2024)

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
The chemerin-CMKLR1 axis in keratinocytes impairs innate host defense against cutaneous Staphylococcus aureus infection
Authors: Yu Chen, Yan Song, Zhe Wang, Yangfan Lai, Wei Yin, Qian Cai, Miaomiao Han, Yiheng Cai, Yushan Xue, Zhengrong Chen, Xi Li, Jing Chen, Min Li, Huabin Li, Rui He
Journal: Cellular and Molecular Immunology (2024)
Diffuse Pulmonary Neuroendocrine Cell Hyperplasia with Parietal Pleural Involvement
Authors: Alexandre Sayadi, Marie-Pierre Debray, Pierre Mordant, Clairelyne Dupin, Alice Guyard
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Diffuse Pulmonary Neuroendocrine Cell Hyperplasia with Parietal Pleural Involvement." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Mitochondrial‐Targeted Copper Delivery for Cuproptosis‐Based Synergistic Cancer Therapy
Authors: Jinpeng Deng, Huilan Zhuang, Sijie Shao, Xuemei Zeng, Panpan Xue, Tingjie Bai, Xiaoman Wang, Shijie Shangguan, Yuanchun Chen, Shuangqian Yan, Wei Huang
Journal: Advanced Healthcare Materials (2024)

Cuproptosis is dependent on mitochondrial respiration modulation by targeting lipoylated tricarboxylic acid cycle (TCA) cycle proteins, showing great potential in cancer treatment. However, the specific release of copper ions at mitochondrial is highly needed and still a major challenge to trigger cellular cuproptosis. Herein, a metal-organic framework-based nanoplatform (ZCProP) is designed for mitochondrial-targeted and ATP/pH-responsive Cu
Mn<sup>2+</sup>‐Mediated Modulation of <i>Pf</i>Ago Activity for Biosensing
Authors: Ruijie Fu, Jinjie Hou, Zexiang Wang, Yunlei Xianyu
Journal: Advanced Healthcare Materials (2024)

Argonaute (Ago) as a powerful enzyme has provided new insights into biosensing due to its programmability, high sensitivity, and user-friendly operation. However, current strategies mainly rely on phosphorylated guide DNA to modulate the cleavage activity of Ago, which is limited in versatility and simplicity. Herein, the authors report the Mn
Clinical Guidelines on Nonalcoholic Fatty Liver Disease
Authors: Alain Braillon
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gender affirming hormone therapy preserves skeletal maturation in young mice via the gut microbiome
Authors: Subhashis Pal, Xochitl Morgan, Hamid Y. Dar, Camilo Anthony Gacasan, Sanchiti Patil, Andreea Stoica, Yi-Juan Hu, M. Neale Weitzmann, Rheinallt M. Jones, Roberto Pacifici
Journal: Journal of Clinical Investigation (2024)

Gender affirming hormone therapy (GAHT) is often prescribed to transgender (TG) adolescents to alleviate gender dysphoria, but the impact of GAHT on the growing skeleton is unclear. We found GAHT to improve trabecular bone structure via increased bone formation in young male mice and not to affect trabecular structure in female mice. GAHT modified gut microbiome composition in both male and female mice. However, fecal microbiota transfers (FMT) revealed that GAHT-shaped gut microbiome was a communicable regulator of bone structure and turnover in male, but not in female mice. Mediation analysis identified two species of Bacteroides as significant contributors to the skeletal effects of GAHT in male mice, with Bacteroides supplementation phenocopying the effects of GAHT on bone. Bacteroides have the capacity to expand Treg populations in the gut. Accordingly, GAHT expanded intestinal regulatory T cells (Tregs) and stimulated their homing to the bone marrow (BM) in male but not in female mice. Attesting to the functional relevance of Tregs, pharmacological blockade of Treg expansion prevented GAHT-induced bone anabolism. In summary, in male mice GAHT stimulated bone formation and improved trabecular structure by promoting Treg expansion via a microbiome-mediated effect. In female mice GAHT neither improved nor impaired trabecular structure.
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Authors: Yueming Zhu, Anupam Banerjee, Ping Xie, Andrey A. Ivanov, Amad Uddin, Qiao Jiao, Junlong Jack Chi, Lidan Zeng, Ji Young Lee, Yifan Xue, Xinghua Lu, Massimo Cristofanilli, William J. Gradishar, Curtis J. Henry, Theresa W. Gillespie, Manali Ajay Bhave, Kevin Kalinsky, Haian Fu, Ivet Bahar, Bin Zhang, Yong Wan
Journal: Journal of Clinical Investigation (2024)

Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic CD8+ T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Authors: Eduardo Sabino de Camargo Magalhães, Stefan Edward Hubner, Brandon Douglas Brown, Yihua Qiu, Steven Mitchell Kornblau
Journal: Leukemia (2024)

The use of Hypomethylating agents combined with Venetoclax (VH) for the treatment of Acute Myeloid Leukemia (AML) has greatly improved outcomes in recent years. However not all patients benefit from the VH regimen and a way to rationally select between VH and Conventional Chemotherapy (CC) for individual AML patients is needed. Here, we developed a proteomic-based triaging strategy using Reverse-phase Protein Arrays (RPPA) to optimize therapy selection. We evaluated the expression of 411 proteins in 810 newly diagnosed adult AML patients, identifying 109 prognostic proteins, that divided into five patient expression profiles, which are useful for optimizing therapy selection. Furthermore, using machine learning algorithms, we determined a set of 14 proteins, among those 109, that were able to accurately recommend therapy, making it feasible for clinical application. Next, we identified a group of patients who did not benefit from either VH or CC and proposed target-based approaches to improve outcomes. Finally, we calculated that the clinical use of our proteomic strategy would have led to a change in therapy for 30% of patients, resulting in a 43% improvement in OS, resulting in around 2600 more cures from AML per year in the United States.
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Authors: Michael Sargent Binkley, Jamie E. Flerlage, Kerry J. Savage, Saad Akhtar, Raphael Steiner, Xiao-Yin Zhang, Michael Dickinson, Anca Prica, Ajay Major, Peter G. Hendrickson, David Hopkins, Andrea Ng, Carla Casulo, Jonathan Baron, Kenneth B. Roberts, Jalila Al Kendi, Alex Balogh, Umberto Ricardi, Pallawi Torka, Lena Specht, Ravindu De Silva, Keir Pickard, Lindsay J Blazin, Michael Henry, Christine M. Smith, Daniel Halperin, Jessica Brady, Bernadette Brennan, Maria Anatolevna Senchenko, Marie Reeves, Bradford S. Hoppe, Stephanie Terezakis, Dipti Talaulikar, Marco Picardi, Youlia Kirova, Paige Fergusson, Eliza A. Hawkes, Denise Lee, Nicole Wong Doo, Allison Barraclough, Chan Y. Cheah, Matthew Ku, Nada Hamad, Howard Mutsando, Michael Gilbertson, Tamara Marconi, Nicholas Viiala, Matthew J Maurer, Dennis A Eichenauer, Richard T. Hoppe, Peter Borchmann, Michael Fuchs, Sylvia Hartmann, Hans Theodor Eich, Andrea C. Lo, Brian Skinnider, M. Shahzad Rauf, Irfan Maghfoor, Chelsea C. Pinnix, Sarah A Milgrom, Francisco Vega, Mohammed Alomari, Graham P. Collins, Ranjana H. Advani, Monika L. Metzger, Andrew Wirth, Richard Tsang, Sonali Smith, Christopher R. Kelsey, Pamela McKay, Julie Koenig, Louis S. Constine, Ku G. Sakthivel, John P. Plastaras, Sarah Gao, Nasser Al Rahbi, Mario Levis, Akshay Sridhar, Nimish Shah, Wendy Osborne, Isabela Chang, Fiona Miall, George Mikhaeel, Anthony Penn, Egor Vasilevich Volchkov, Roberta Della Pepa, Michael Northend, Stephen Opat, Ross Salvaris, Aditya Tedjaseputra, Monica Palese, Ananth Shankar, Yasodha Natkunam, Kara M. Kelly
Journal: Journal of Clinical Oncology (2024)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL.
Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus
Authors: Erica Moore, Sushma Bharrhan, Deepak A Rao, Fernando Macian, Chaim Putterman
Journal: Annals of the Rheumatic Diseases (2024)

Objective Diffuse central nervous system manifestations, referred to as neuropsychiatric lupus (NPSLE), are observed in 20–40% of lupus patients and involve complex mechanisms that have not yet been adequately elucidated. In murine NPSLE models, choroid plexus (ChP)-infiltrating T cells have not been fully evaluated as drivers of neuropsychiatric disease. Method Droplet-based single-cell transcriptomic analysis (single-cell RNA sequencing) and immune T-cell receptor profiling were performed on ChP tissue from MRL/lpr mice, an NPSLE mouse model, at an ‘early’ and ‘late’ disease state, to investigate the infiltrating immune cells that accumulate with NPSLE disease progression. Results We found 19 unique clusters of stromal and infiltrating cells present in the ChP of NPSLE mice. Higher resolution of the T-cell clusters uncovered multiple T-cell subsets, with increased exhaustion and hypoxia expression profiles. Clonal analysis revealed that the clonal CD8+T cell CDR3 sequence, ASGDALGGYEQY, matched that of a published T-cell receptor sequence with specificity for myelin basic protein. Stromal fibroblasts are likely drivers of T-cell recruitment by upregulating the VCAM signalling pathway. Systemic blockade of VLA-4, the cognate ligand of VCAM, resulted in significant resolution of the ChP immune cell infiltration and attenuation of the depressive phenotype. Conclusion Our analysis details the dynamic transcriptomic changes associated with murine NPSLE disease progression, and highlights its potential use in identifying prospective lupus brain therapeutic targets.
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Authors: Eleftheria Kalogera, Wendy K. Nevala, Heidi D. Finnes, Vera J. Suman, Jill M. Schimke, Carrie A. Strand, Lisa A. Kottschade, Rachel A. Kudgus, Sarah A. Buhrow, Laura R. Becher, Liyi Geng, Gretchen E. Glaser, Megan E. Grudem, Aminah Jatoi, Carolyn M. Klampe, Amanika Kumar, Carrie L. Langstraat, Robert R. McWilliams, Andrea E. Wahner Hendrickson, S. John Weroha, Yiyi Yan, Joel M. Reid, Svetomir N. Markovic, Matthew S. Block
Journal: Clinical Cancer Research (2024)

AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared with sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers.
Exclusive Breastfeeding Duration and Risk of Childhood Cancers
Authors: Signe Holst Søegaard, Mie Mølgaard Andersen, Klaus Rostgaard, Olafur Birgir Davidsson, Sjurdur Frodi Olsen, Kjeld Schmiegelow, Henrik Hjalgrim
Journal: JAMA Network Open (2024)

Importance Breastfeeding has been suggested to protect against childhood cancers, particularly acute lymphoblastic leukemia (ALL). However, the evidence stems from case-control studies alone. Objective To investigate whether longer duration of exclusive breastfeeding is associated with decreased risk of childhood ALL and other childhood cancers. Design, Setting, and Participants This population-based cohort study used administrative data on exclusive breastfeeding duration from the Danish National Child Health Register. All children born in Denmark between January 2005 and December 2018 with available information on duration of exclusive breastfeeding were included. Children were followed up from age 1 year until childhood cancer diagnosis, loss to follow-up or emigration, death, age 15 years, or December 31, 2020. Data were analyzed from March to October 2023. Exposure Duration of exclusive breastfeeding in infancy. Main Outcomes and Measures Associations between duration of exclusive breastfeeding and risk of childhood cancer overall and by subtypes were estimated as adjusted hazard ratios (AHRs) with 95% CIs using stratified Cox proportional hazards regression models. Results A total of 309 473 children were included (51.3% boys). During 1 679 635 person-years of follow-up, 332 children (0.1%) were diagnosed with cancer at ages 1 to 14 years (mean [SD] age at diagnosis, 4.24 [2.67] years; 194 boys [58.4%]). Of these, 124 (37.3%) were diagnosed with hematologic cancers (81 [65.3%] were ALL, 74 [91.4%] of which were B-cell precursor [BCP] ALL), 44 (13.3%) with central nervous system tumors, 80 (24.1%) with solid tumors, and 84 (25.3%) with other and unspecified malignant neoplasms. Compared with exclusive breastfeeding duration of less than 3 months, exclusive breastfeeding for 3 months or longer was associated with a decreased risk of hematologic cancers (AHR, 0.66; 95% CI, 0.46-0.95), which was largely attributable to decreased risk of BCP-ALL (AHR, 0.62; 95% CI, 0.39-0.99), but not with risk of central nervous system tumors (AHR, 0.96; 95% CI, 0.51-1.88) or solid tumors (AHR, 0.87; 95% CI, 0.55-1.41). Conclusions and Relevance In this cohort study, longer duration of exclusive breastfeeding was associated with reduced risk of childhood BCP-ALL, corroborating results of previous case-control investigations in this field. To inform future preemptive interventions, continued research should focus on the potential biologic mechanisms underlying the observed association.
Just how transformative will AI/ML be for immuno-oncology?
Authors: Daniel Bottomly, Shannon McWeeney
Journal: Journal for ImmunoTherapy of Cancer (2024)

Immuno-oncology involves the study of approaches which harness the patient's immune system to fight malignancies. Immuno-oncology, as with every other biomedical and clinical research field as well as clinical operations, is in the midst of technological revolutions, which vastly increase the amount of available data. Recent advances in artificial intelligence and machine learning (AI/ML) have received much attention in terms of their potential to harness available data to improve insights and outcomes in many areas including immuno-oncology. In this review, we discuss important aspects to consider when evaluating the potential impact of AI/ML applications in the clinic. We highlight four clinical/biomedical challenges relevant to immuno-oncology and how they may be able to be addressed by the latest advancements in AI/ML. These challenges include (1) efficiency in clinical workflows, (2) curation of high-quality image data, (3) finding, extracting and synthesizing text knowledge as well as addressing, and (4) small cohort size in immunotherapeutic evaluation cohorts. Finally, we outline how advancements in reinforcement and federated learning, as well as the development of best practices for ethical and unbiased data generation, are likely to drive future innovations.
Sleep, mental health and physical health in new shift workers transitioning to shift work: Systematic review and meta-analysis
Authors: Rachael Harris, Eleni Kavaliotis, Sean P.A. Drummond, Alexander P. Wolkow
Journal: Sleep Medicine Reviews (2024)

This systematic review and meta-analysis (PROSPERO registration CRD42022309827) aimed to describe how shift work impacts new workers' sleep, mental health, and physical health during the transition to shift work and to consolidate information regarding predictors of shift work tolerance (SWT) during this transition period. Inclusion criteria included: new shift workers; sleep, mental health, or physical health outcomes; prospective study design with the first timepoint assessing workers within three months of starting shift work; and written in English. Searches from six databases returned 12,172 articles as of August 2023. The final sample included 48 papers. Publication quality and risk of bias was assessed using the critical appraisal skills program. Forty-five studies investigated longitudinal changes in sleep, mental health, or physical health outcomes and 29 studies investigated predictors of SWT (i.e., better sleep, mental and physical health). Sleep and mental health outcomes worsened following the onset of shift work, while physical health did not significantly change. Pre-shift work mental health, sleep, and work characteristics predicted SWT later in workers' careers. Shift work adversely impacts new workers' sleep and mental health early in their career, and interventions before beginning shift work are needed to promote better SWT.
A functional 3D full-thickness model for comprehending the interaction between airway epithelium and connective tissue in cystic fibrosis
Authors: Claudia Mazio, Laura Sara Scognamiglio, Costantino Casale, Valeria Panzetta, Francesco Urciuolo, Luis J.V. Galietta, Giorgia Imparato, Paolo A. Netti
Journal: Biomaterials (2024)

Patients with cystic fibrosis (CF) experience severe lung disease, including persistent infections, inflammation, and irreversible fibrotic remodeling of the airways. Although therapy with transmembrane conductance regulator (CFTR) protein modulators reached optimal results in terms of CFTR rescue, lung transplant remains the best line of care for patients in an advanced stage of CF. Indeed, chronic inflammation and tissue remodeling still represent stumbling blocks during treatment, and underlying mechanisms are still unclear. Nowadays, animal models are not able to fully replicate clinical features of the human disease and the conventional in vitro models lack a stromal compartment undergoing fibrotic remodeling. To address this gap, we show the development of a 3D full-thickness model of CF with a human bronchial epithelium differentiated on a connective airway tissue. We demonstrated that the epithelial cells not only underwent mucociliary differentiation but also migrated in the connective tissue and formed gland-like structures. The presence of the connective tissue stimulated the pro-inflammatory behaviour of the epithelium, which activated the fibroblasts embedded into their own extracellular matrix (ECM). By varying the composition of the model with CF epithelial cells and a CF or healthy connective tissue, it was possible to replicate different moments of CF disease, as demonstrated by the differences in the transcriptome of the CF epithelium in the different conditions. The possibility to faithfully represent the crosstalk between epithelial and connective in CF through the full thickness model, along with inflammation and stromal activation, makes the model suitable to better understand mechanisms of disease genesis, progression, and response to therapy.